RT Journal Article
SR Electronic
T1 Humoral immune response of patients infected by earlier lineages of SARS-CoV-2 neutralizes wild types of the most prevalent variants in Brazil
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.24.22269379
DO 10.1101/2022.01.24.22269379
A1 Pauvolid-Corrêa, Alex
A1 Caetano, Braulia Costa
A1 Machado, Ana Beatriz
A1 Araújo Ferreira, Mia
A1 Valente, Natalia
A1 Neves, Thayssa Keren
A1 Geraldo, Kim
A1 Motta, Fernando
A1 Gonçalves Veloso dos Santos, Valdiléa
A1 Grinsztejn, Beatriz
A1 Mendonça Siqueira, Marilda
A1 Resende, Paola Cristina
YR 2022
UL http://medrxiv.org/content/early/2022/01/28/2022.01.24.22269379.abstract
AB In the present study, serum samples of 20 hospitalized COVID-19 patients from Brazil who were infected by the earlier SARS-CoV-2 lineages B.1.1.28 and B.1.1.33, and by the variant of concern (VOC) Gamma (P.1) were tested by plaque reduction neutralization test (PRNT90) with wild isolates of a panel of SARS-CoV-2 lineages, including B.1, Zeta, N.10, and the VOCs Gamma, Alpha, and Delta that emerged in different timeframes of the pandemic. The main objectives of the present study were to evaluate if serum of COVID-19 patients infected by earlier lineages of SARS-CoV-2 were capable to neutralize recently emerged VOCs, and if PRNT90 is a reliable serologic method to distinguish infections caused by different SARS-CoV-2 lineages. Overall, sera collected from the day of admittance to the hospital to 21 days after diagnostic of patients infected by the two earlier lineages B.1.1.28 and B.1.1.33 presented neutralizing capacity for all challenged VOCs, including Gamma and Delta, that were the most prevalent VOCs in Brazil. Among all variants tested, Delta and N.10 presented the lowest mean of neutralizing antibody titers, and B.1.1.7, presented the highest titers. Four patients infected with Gamma, that emerged in December 2020, presented neutralizing antibodies for B.1, B.1.1.33 and B.1.1.28, its ancestor lineage. All of them had neutralizing antibodies under the level of detection for the VOC Delta. Interestingly, patients infected by B.1.1.28 presented very similar mean of neutralizing antibody titers for both B.1.1.33 and B.1.1.28. Findings presented here indicate that most patients infected in early stages of COVID-19 pandemic presented neutralizing antibodies up to 21 days after diagnostic capable to neutralize wild types of all recently emerged VOCs in Brazil, and that the PRNT90 it is not a reliable serologic method to distinguish natural infections caused by different SARS-CoV-2 lineages.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by: General Laboratories Coordination of Brazilian Ministry of Health; the Coordination of Health Surveillance and Reference Laboratories of Oswaldo Cruz Foundation; Ministerio da Ciencia, Tecnologia, Inovacoes e Comunicacoes/Conselho Nacional de Desenvolvimento Cientifico e Tecnologico CNPq/Ministerio da SaudeMS/FNDCT/SCTIE/Decit (grants no. 402457/2020-9 and 403276/2020-9); Inova Fiocruz/Fundacao Oswaldo Cruz (grants no. VPPCB-007-FIO-18-2-30; FAPERJ: E26/210.196/2020).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Ethics Committee of the Fundacao Oswaldo Cruz (CAAE 68118417.6.0000.5248), and the Ethics Committee of the National Institute of Infectious Diseases (CAAE 32449420.4.1001.5262).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors